linjc16/ctgov huggingface dataset:
Electronic Health Record (EHR)-Based Intervention for Gastroesophageal Reflux Disease (GERD) and Chronic Non-steroidal Anti-inflammatory Drug (NSAID) Use

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to examine the impact of augmented, high-quality physician-coordinated care executed via an electronic health record (EHR)-based intervention on quality of care for gastroesophageal reflux disease (GERD) and for gastroprotection for patients on chronic non-steroidal anti-inflammatory drugs (NSAIDs) at increased risk for upper GI tract ulcers and ulcer related complications.

Official Title
-----------------
Using an Electronic Health Record-based Intervention and Broad Education Reach Strategies to Improve Quality of Care for GERD and Gastroprotection for Patients on NSAIDs: a Randomized Controlled Trial

Conditions
-----------------
GERD

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Eligibility as determined by criteria for participation in studies as part of the MQIC Agreement of participating clinical practices to undergo training in the electronic health record (EHR) intervention designed for this study Exclusion Criteria: Based on voluntary participation by MQIC practices, so practices were excluded if they decided to opt out

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>GERD: Patients with established diagnoses of GERD based on ICD-9 codes | |
| 2<br>Atypical GERD: Patients without an established diagnosis of GERD with atypical symptoms that could be due to GERD (e.g., asthma) | |
| 3<br>Chronic NSAID users: Patients using chronic NSAIDs who are at increased risk of GI complications (defined as previous diagnosis of peptic ulcer disease; age 75 or older; or concomitant use of corticosteroids, anticoagulants, or aspirin) | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnoses of GERD |  | After 12 months of intervention | 
| Prescriptions for gastroprotective medicines in at-risk, chronic NSAID users |  | After 12 months of intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Prescriptions for GERD medications |  | After 12 months of intervention | 
| Change in GERD symptoms score |  | After 12 months of intervention | 
| NSAID-related GI complications |  | After 12 months of intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
gastroesophageal reflux disease, GERD, nonsteroidal anti-inflammatory drugs, peptic ulcer, Diagnosed GERD, Atypical GERD symptoms, chronic NSAID therapy, Risk for ulcer
Efficacy of Local Food Extracts at Different Storage Times

Study Overview
=================
Brief Summary
-----------------
Local lyophylized food extracts are available useful in skin prick test and atopy patch test to confirm food allergy. However, the investigators want to know the duration that the investigators can keep the extracts for the usage in this purpose.

Detailed Description
-----------------
Food allergy incidence increases world wide. The diagnosis mostly depends on history. Skin prick test and atopic patch test are useful in finding the causative foods in some cases. The local food extracts have been shown to be at least as effective as commercial ones. From previous study the investigators keep the extract at 2-8 degree Celsius for 1-3 months for the usage. The investigators want to evaluate the duration that the extracts are still useful in diagnosis food allergy

Official Title
-----------------
Efficacy of Local Lyophilized Food Extracts for Skin Prick Tests and Atopy Patch Test at Different Storage Times (0, 3 and 6 Months)

Conditions
-----------------
Food Allergy

Intervention / Treatment
-----------------
* Other: prick and patch test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Positive skin prick test to one of the food (milk, egg, soy, wheat, seafood) Exclusion Criteria: Chronic diseases such as heart disease, liver, renal and severe sepsis Severe allergic symptoms such as anaphylaxis Extensive skin rashes Pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean wheal diameter of skin prick test | The skin prick tests are performed with local prepared food allergen at keeping time of 0, 3 and 6 months after the preparation. | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Result of atopy patch test | atopy patch tests are performed with local prepared food allergen at keeping time of 0, 3 and 6 months after the preparation. | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
food allergy, skin prick test, atopy patch test
Pharmacogenetic Study for Topiramate-Induced Cognitive Dysfunction

Study Overview
=================
Brief Summary
-----------------
Topiramate (TPM) is an antiepileptic drug with a unique mode of action that is often useful in patients refractory to other drugs. However its use is restricted by the high incidence of cognitive adverse drug reactions (ADRs) that are associated with TPM exposure. TPM has been shown to cause particular cognitive ADRs, characterized by verbal fluency, attention, working memory and language deficits, at a much higher rate than other antiepileptic drugs. There do not appear to be obvious differences between patients that do or do not experience cognitive ADRs when on TPM (e.g. age, sex, concomitant medications, diagnosis), which suggests a genetic contributor.

Conditions
-----------------
Cognitive Dysfunction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adult (>17 years old) patients with epilepsy or patients with migraine treated by topiramate Exclusion Criteria: allergy to topiramate abnormal liver or renal function

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pharmacogenetic, study, Topirmate, induced
Personalized DC Vaccine for Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The study is aimed to the test the efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for refractory non-small cell lung cancer.

Detailed Description
-----------------
Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial. Patients' rebiopsy tumor tissues are subsequent to whole exosome sequencing and possible neoantigens are identified. DC is in vitro primed with synthesized peptides. Both adverse events and responses are recorded.

Official Title
-----------------
Neoantigen-primed DC Vaccine Therapy for Refractory Non-small Cell Lung Cancer

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Biological: DC vaccine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: pathologically confirmed non-small cell lung cancer failed in previous standard chemotherapy and targeted therapy anticipated life time > 3month Karnofsky performance status 0-1 rehabilitate from previous therapy adequate organ functions Exclusion Criteria: mixed histological types tumor emergency abnormal coagulation condition contagious diseases, such as hepatitis B virus, hepatitis C virus, human immunodefficiency virus, tuberculosis infection concomitant tumors immunological co-morbidities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: cell_therapy<br>tumor neoantigen primed DC vaccines are administrated, 2-week interval, totally 5 times | Biological: DC vaccine<br>* subcutaneous administration<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 3 months after the last administration of cells | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| objective response rate | Number of participants with objective responses as assayed by RECIST 1.1 | through study completion, an average of 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
advanced non-small cell lung cancer, cell based therapy, safety, clinical efficacy
Treatment of BV With First Deqularum and Then Direkt After Clindamycin

Study Overview
=================
Brief Summary
-----------------
Treatment of BV with first deqularum cloride and then followed with clindamycin vaginal Cream.

Detailed Description
-----------------
The hypoteses is that deqularum cloride takes away the biofilm so that clindamycin will kills the bacteria. Cure rate will be followed up after 1 month and then after 6 month

Official Title
-----------------
Treatment of BV With First Deqularum and Then Direkt After With Vaginal Clindamycin Cream.

Conditions
-----------------
Infection, Bacterial

Intervention / Treatment
-----------------
* Drug: treatment of BV with first Deqularum and then direkt after with vaginal clindamycin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: healthy women with BV Exclusion Criteria: women treated with antibiotics within 1 month

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: treatment of BV<br>all patients be treated with first Deqularum then with clindamycin Cream, | Drug: treatment of BV with first Deqularum and then direkt after with vaginal clindamycin<br>* All patients will get the same treatment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cure of BV | cure rate of BV | 6 month |
Study to Investigate the Causes of Fever in Children Living in Urban Dar es Salaam and Rural Ifakara

Study Overview
=================
Brief Summary
-----------------
The goal is to improve the evidence-based management of fever cases seen in outpatient clinics in malaria endemic countries, through a better understanding of the value of accurate malaria diagnosis, and through an improved understanding of the other causes of fever in children. The objective is to describe systematically (as much as possible) the etiologies of fever in children in an urban and in a rural environment of sub-Saharan Africa.

Official Title
-----------------
Study to Investigate the Causes of Fever in Children Living in Urban Dar es Salaam and Rural Ifakara

Conditions
-----------------
Fever, Children, Infectious Diseases

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: axillary temperature of 38°C or more first consultation for the present problem history of fever lasting for one week or less main complaint was not an injury or trauma no report of an antimalarial or antibiotic medicine taken during the previous week Exclusion Criteria: severe malnutrition categorized as P1 (requiring immediate live saving procedures)

Ages Eligible for Study
-----------------
Minimum Age: 2 Months
Maximum Age: 10 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of each disease and proportion of fevers of unknown origin in febrile children aged 2 months to 10 years attending an Outpatient Department of a district hospital in Dar es Salaam and in Ifakara |  | December 2011 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical and laboratory predictors of each disease |  | December 2011 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fever, Children, Non-malaria fevers, Diagnosis
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic

Study Overview
=================
Brief Summary
-----------------
Automated quantification of the pulmonary volume impaired during acute respiratory failure could be helpful to assess patient severity during COVID-19 infection or perioperative medicine, for example. This study aims at assessing the correlation between the amount of radiologic pulmonary alteration and the clinical severity in two clinical situation : SARS-CoV-2 infections Postoperative hypoxemic acute respiratory failure.

Official Title
-----------------
Automated Quantification of Radiologic Pulmonary Alteration During Acute Respiratory Failure: Application to the COVID-19 Pandemic : Prospective Multicenter Cohort Study

Conditions
-----------------
SARS-CoV-2 Infections, Respiratory Failure With Hypoxia

Intervention / Treatment
-----------------
* Radiation: Thoracic CT scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject admitted to a care unit of the University Hospitals of Strasbourg or the University Hospital of Nancy and presenting a suspicion of SARS-CoV-2 infection or postoperative hypoxemic respiratory failure Able to understand the objectives and risks of the research and to give dated and signed informed consent. Subjects may also be included in emergency or immediate life-threatening situations. Subject with insurance covering Exclusion Criteria: Pregnant woman (pregnancy confirmed by a urine or blood test) Subject usually on home oxygen therapy Subject under court protection Subject under guardianship or curatorship

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Thoracic CT Scan<br> | Radiation: Thoracic CT scan<br>* Automated quantitative analysis of altered pulmonary volume<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between altered pulmonary volume and ordinal severity scale | This criterion will be expressed as a score between 1 (least severe) and 7 (most severe). | 2 days after CT scan (Day 2) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between altered pulmonary volume and ordinal severity scale | This criterion will be expressed as a score between 1 (least severe) and 7 (most severe). | 7 days after CT scan (Day 7) | 
| Mortality |  | 90 days following CT scan (Day 90) | 
| Rate of admission to intensive care unit |  | 28 days following CT scan (Day 28) | 
| Initial length of hospitalization stay (in days) |  | 90 days following CT scan (Day 90) |
Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether dynamic contrast enhanced MRI (DCE MRI) and high diffusion weighting MRI may be used to distinguish between favorable and unfavorable responses to therapy of glioblastoma multiforme. Imaging data will be correlated with histopathologic findings and clinical responses to radiation therapy with or without chemotherapy.

Official Title
-----------------
Early Detection of Glioblastoma Multiforme (GBM) Treatment Responses Using Multiple Magnetic Resonance Modalities

Conditions
-----------------
Glioblastoma Multiforme

Intervention / Treatment
-----------------
* Other: dynamic contrast enhanced magnetic resonance imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The presence of a primary brain tumor that cannot be completely resected that requires radiation therapy with or without chemotherapy. Exclusion Criteria: Patients who do not have a primary brain tumor or who are unable to tolerate the environment of the MRI scanner

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br> | Other: dynamic contrast enhanced magnetic resonance imaging<br>* dynamic contrast enhanced MRI using contrast agent gadodiamide<br>* Other names: Omniscan;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To detect the early local treatment responses from the physician recognized GBM gross tumor volume (GTV) |  | Upon completion of study |
Impact of Corona Vaccination on AMH- Anti Mullerian Hormone

Study Overview
=================
Brief Summary
-----------------
Since December 2020 Nationwide anti-COVID-19 vaccination began in Israel using the Pfizer - BioNtech vaccine (BNT162b2 mRNA). The vaccination campaign has been associated with concerns regarding potential detrimental effects on future fertility. The aim of the study is to determine the impact of COVID-19 vaccination on n AMH- Anti Mullerian Hormone which express ovarin function. disease and/or immunization on human follicular function, by comparing follicular steroidogenesis, response to the LH/hCG trigger, and oocyte quality biomarker (HSPG2), in the aspirated follicular fluid of patients undergoing ovum pick-up.

Detailed Description
-----------------
Our assumption is that there is no effect of the vaccination on the AMH level. We plan to recruit 90 patients who are divided to three groups First group patients who vaccinated and measure the AMH before and up to 9 months after vaccination. Second group patients who were infected by Covid-19 ant therefor were not vaccinated to compare the AMH level before and after the infectious. The third group patients who were not infected and not vaccinated.

Official Title
-----------------
Wether Corona Vaccination Has Negative Impact on AMH- Anti Mullerian Hormone Which Express Ovarin Function

Conditions
-----------------
Patient Participation

Intervention / Treatment
-----------------
* Biological: Vcinated


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-44 Exclusion Criteria: Age over 45

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 44 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Vaciinated<br>First group patients who vaccinated and measure the AMH before and up to 9 months after vaccination. | Biological: Vcinated<br>* Patients who were vacinated.<br>|
| Infected patients by covid-19 and not vacinated<br>Second group patients who were infected by Covid-19 ant therefor were not vaccinated | |
| Not infected nor vacinated<br>Ptients who who were not infected nor vacinated by Covid-19. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Amh levels | Before and after vacination | 9 months |